CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00123104" target="_blank" >RIV/00216224:14110/21:00123104 - isvavai.cz</a>
Result on the web
<a href="https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext" target="_blank" >https://www.annalsofoncology.org/article/S0923-7534(21)03785-6/fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.annonc.2021.08.1556" target="_blank" >10.1016/j.annonc.2021.08.1556</a>
Alternative languages
Result language
angličtina
Original language name
CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
Original language description
SARS-CoV-2 infection may be a threat for those undergoing active anti-cancer therapy. We aim to study adverse events, efficacy, and immune response in Covid-19 vaccinated patients focusing on possibly interfering therapy.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů